Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) has issued an announcement.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced the approval and upcoming launch of its Encofosbuvir Tablets, a Class I innovative drug for treating Hepatitis C. This approval marks a significant milestone for the company, enhancing its competitive edge in the hepatitis C treatment market and reinforcing its position as a leader among innovative pharmaceutical companies in China.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceutical company based in China, focusing on innovative drug development. The company has a strong presence in the primary healthcare market, particularly in the hepatitis C drug sector, with a comprehensive portfolio of drug products.
YTD Price Performance: 0.84%
Average Trading Volume: 3,014,209
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.48B
For a thorough assessment of 1558 stock, go to TipRanks’ Stock Analysis page.